Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech develops and manufactures biosimilar medicines for global markets. Company news centers on its approved and marketed biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, along with disclosed candidates for autoimmune disorders, eye disorders, osteoporosis, respiratory disease and cancer.
Recurring updates cover financial results, annual reporting, FDA interactions tied to the Reykjavik manufacturing facility, biosimilar study results such as AVT80, supply and commercialization partnerships, intellectual-property settlements, executive changes and manufacturing-platform developments. Alvotech also reports on global commercial reach through partners across the United States, Europe, Japan, China and other international markets.
Alvotech (ALVO) disclosed manager-related transactions involving a significant share pledge. Filings with Luxembourg's CSSF report that Celtic Lux Holdings pledged 88,940,619 shares and 7,007,321 depository receipts in Alvotech. The transactions, classified as dealings by managers and closely associated persons, were dated June 26, 2026.
Alvotech (NASDAQ: ALVO) amended its credit agreement to add a $75 million term loan facility maturing December 31, 2027, led by GoldenTree Asset Management. The loan bears 12.50% interest, payable monthly in cash.
Alongside a recent $165 million equity raise and an existing $100 million term loan, Alvotech now has access to $240 million in new capital to fund its biosimilar R&D pipeline, FDA-related activities, product launches and global commercial expansion.
Alvotech (NASDAQ: ALVO) reported a managers and closely associated persons transaction filed with Luxembourg’s CSSF. Celtic Lux Holdings S.a. r.l. acquired 10,133,333 Alvotech shares on June 16, 2026 at USD 3.75 per share. The filing includes contact details for Alvotech investor relations.
Alvotech (NASDAQ: ALVO) commenced an underwritten public offering of ordinary shares and a concurrent private placement, with anticipated combined gross proceeds of approximately $125 million. Underwriters may receive a 30-day option to buy up to 15% additional shares. All shares will be newly issued by Alvotech.
Net proceeds are intended to fund biosimilar development, working capital and general corporate purposes, including R&D, commercialization activities, capital expenditures, potential acquisitions or collaborations, and possible repayment or refinancing of debt.
Alvotech (NASDAQ: ALVO) closed an underwritten public offering of 26,066,667 ordinary shares at $3.75 per share on June 17, 2026, raising about $98 million gross. Concurrently, it agreed to a private placement of 17,826,666 shares for about $67 million, totaling expected gross proceeds of $165 million.
The private placement is expected to close on or about June 25, 2026. In total, 43,893,333 new shares will be issued, bringing share capital to 390,431,480 shares. Proceeds will fund biosimilar development, working capital and general corporate purposes.
Alvotech (NASDAQ: ALVO) priced an underwritten public offering of 22,666,667 ordinary shares at $3.75 per share, targeting gross proceeds of about $85 million, or $98 million if underwriters exercise a 3.4 million-share option.
A concurrent private placement of 17,826,666 shares at $3.75 is expected to raise about $67 million, bringing total gross proceeds to roughly $152–165 million. According to Alvotech, net proceeds will support biosimilar development, working capital, general corporate purposes and possible debt repayment.
Alvotech (NASDAQ: ALVO) has launched an underwritten public offering of ordinary shares and a concurrent private placement, targeting approximately $125 million in gross proceeds. A 30-day underwriter option for up to 15% additional shares is expected. Proceeds will fund biosimilar development, working capital and general corporate purposes.
Alvotech (ALVO) published a filing with the Luxembourg financial regulator CSSF detailing a manager transaction.
The filing reports the allocation of shares to a board director, granted in accordance with his agreed remuneration package, and is disclosed as a transaction of managers and closely associated persons.
Alvotech (NASDAQ: ALVO) announced FDA acceptance for review of its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) IV. Under its partnership with Teva, Alvotech handles development and manufacturing, while Teva leads commercialization.
The BLA is backed by analytical, pharmacokinetic and immunogenicity data to support biosimilarity. AVT16 targets adults with moderately to severely active ulcerative colitis and Crohn’s disease. A pivotal pharmacokinetic study of AVT80, another Entyvio biosimilar candidate, met all primary endpoints and supports clinical similarity for both AVT16 and AVT80.
Alvotech (NASDAQ: ALVO) resubmitted U.S. FDA Biologics License Applications for AVT05, a proposed biosimilar to Simponi and Simponi Aria, and AVT06, a proposed biosimilar to Eylea 2 mg.
The resubmissions follow responses to an FDA Post-Application Action Letter and cGMP inspection observations at Alvotech’s Reykjavik facility. The company expects a six-month FDA review.